Cytek Biosciences, Inc.

NASDAQ:CTKB

Medical - Devices

Healthcare
$5.92 -2.64%

-$0.11 today

Market cap
$774.24M
Beta
1.19
P/E (TTM)
-6.7
EPS (TTM)
-$0.57
52W Low $2.90High $6.18

Volume 1.05M

Average 0.88M

CTKB Income Before Tax

Profit after all operating and non-operating items but before income tax.

Cytek Biosciences, Inc.NASDAQ: CTKB

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$17.37M, compared with -$11.27M a year earlier. Trailing-twelve-month income before tax was -$35.95M.

Context

  • Income before tax amounted to 14.8% of revenue in FY2025, up 12.0 pp from a year earlier.
  • Income before tax increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$17.37M or moves back toward the trailing-twelve-month quarterly average of -$8.99M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.37M-331.0% QoQ
Last fiscal yearDec 2025
-$29.84M-423.5% YoY
LTMMar 2026
-$35.95M-350.9% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.2%——
1 year-423.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(29.84M) USD
Year-over-year change
-423.5%

Income Before Tax vs competitors

How CTKB compares with its peers on the latest reported figures

  • CTKB's LTM Mar 2026 income before tax of -$35.95M is the 4th highest of the 6 companies compared; the peer median is -$28.1M.
  • Its year-over-year change of -350.9% is the lowest of 6, against a peer median of +10.9%.
  • Income before tax amounts to 17.6% of revenue for CTKB, versus a peer median of 13.5%.
CTKB Competitors Peer median
Income Before Tax for CTKB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAgilent Technologies, Inc.LTM Jul 2026$1.66B +18.9%-1.6%22.5%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$350.4M -22.2%—13.5%
BRKRBruker CorporationLTM Jun 2026-$28.1M -120.6%-63.0%0.8%
CTKBCytek Biosciences, Inc.LTM Mar 2026-$35.95M -350.9%—17.6%
TXG10x Genomics, Inc.LTM Sep 2026-$65.16M +10.9%—10.5%
LABStandard BioTools Inc.LTM Mar 2026-$87.83M +19.8%—101.8%
Peer median (excluding CTKB) -$28.1M+10.9%-32.3%13.5%

Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue127.95M164.04M193.02M200.45M201.49M
Cost of Revenue48.81M63.06M83.59M89.35M97.03M
Gross Profit79.14M100.97M109.43M111.11M104.46M
Gross Margin61.9%61.6%56.7%55.4%51.8%
Research & Development24.44M34.86M44.15M39.4M36.47M
Selling, General & Admin45.55M67.92M93.12M92.23M108.38M
Operating Expenses69.99M102.78M137.27M131.63M144.84M
Depreciation & Amortization1.24M5.66M9.23M10.49M11.98M
EBITDA8.92M9.49M(4.41M)4.79M(17.39M)
EBITDA Margin7.0%5.8%-2.3%2.4%-8.6%
Operating Income9.16M(1.8M)(27.85M)(20.52M)(40.38M)
Operating Margin7.2%-1.1%-14.4%-10.2%-20.0%
Interest Income49K4.62M6.41M10.36M2.22M
Interest Expense1.74M2.57M2.07M0474K
Other Income / Expenses(3.22M)3.06M12.14M14.82M10.54M
Income Before Tax5.94M1.26M(15.71M)(5.7M)(29.84M)
Pre-Tax Margin4.6%0.8%-8.1%-2.8%-14.8%
Income Tax Expense2.91M(1.22M)(3.56M)320K36.7M
Net Income3M2.58M(12.15M)(6.02M)(66.54M)
Net Margin2.3%1.6%-6.3%-3.0%-33.0%
EPS (Basic)0.030.02(0.09)(0.05)(0.52)
EPS (Diluted)0.030.02(0.09)(0.05)(0.52)
Weighted Avg Shares133.75M134.51M135.28M130.61M127.75M
Weighted Avg Shares (Diluted)133.75M138.56M135.28M130.61M127.75M

Cytek Biosciences, Inc.

NASDAQ:CTKB

Intrinsic Alpha fair value

Locked

Current Price

$5.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.